Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Azenosertib by Zentalis Pharmaceuticals for Secondary Acute Myeloid Leukemia: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Secondary Acute Myeloid Leukemia. According to...
Azenosertib by Zentalis Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Azenosertib by Zentalis Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Azenosertib by Zentalis Pharmaceuticals for Osteosarcoma: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Azenosertib by Zentalis Pharmaceuticals for Epithelial Ovarian Cancer: Likelihood of Approval
Azenosertib is under clinical development by Zentalis Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Zentalis Pharmaceuticals's Azenosertib?
Azenosertib is a small molecule commercialized by Zentalis Pharmaceuticals, with a leading Phase II program in Human Epidermal Growth Factor...